These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23313564)

  • 61. Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants.
    Ricken R; Adli M; Lange C; Krusche E; Stamm TJ; Gaus S; Koehler S; Nase S; Bschor T; Richter C; Steinacher B; Heinz A; Rapp MA; Borgwardt S; Hellweg R; Lang UE
    J Clin Psychopharmacol; 2013 Dec; 33(6):806-9. PubMed ID: 24018547
    [TBL] [Abstract][Full Text] [Related]  

  • 62. BDNF plasma levels variations in major depressed patients receiving duloxetine.
    Fornaro M; Escelsior A; Rocchi G; Conio B; Magioncalda P; Marozzi V; Presta A; Sterlini B; Contini P; Amore M; Fornaro P; Martino M
    Neurol Sci; 2015 May; 36(5):729-34. PubMed ID: 25501804
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.
    Lohoff FW; Aquino TD; Narasimhan S; Multani PK; Etemad B; Rickels K
    Pharmacogenomics J; 2013 Feb; 13(1):21-6. PubMed ID: 22006095
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.
    Davidson J; Allgulander C; Pollack MH; Hartford J; Erickson JS; Russell JM; Perahia D; Wohlreich MM; Carlson J; Raskin J
    Hum Psychopharmacol; 2008 Aug; 23(6):519-26. PubMed ID: 18478624
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.
    Li X; Zhu L; Zhou C; Liu J; Du H; Wang C; Fang S
    PLoS One; 2018; 13(3):e0194501. PubMed ID: 29558528
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials.
    Zhang Y; Huang G; Yang S; Liang W; Zhang L; Wang C
    Asia Pac Psychiatry; 2016 Sep; 8(3):215-25. PubMed ID: 26238298
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.
    Strawn JR; Prakash A; Zhang Q; Pangallo BA; Stroud CE; Cai N; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):283-93. PubMed ID: 25791145
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.
    Perlis RH; Fijal B; Dharia S; Houston JP
    Pharmacogenomics J; 2013 Jun; 13(3):280-5. PubMed ID: 22249355
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An open-label trial of risperidone augmentation for refractory anxiety disorders.
    Simon NM; Hoge EA; Fischmann D; Worthington JJ; Christian KM; Kinrys G; Pollack MH
    J Clin Psychiatry; 2006 Mar; 67(3):381-5. PubMed ID: 16649823
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
    Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.
    Baldwin DS; Loft H; Florea I
    Int Clin Psychopharmacol; 2012 Jul; 27(4):197-207. PubMed ID: 22475889
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Implications of pain in generalized anxiety disorder: efficacy of duloxetine.
    Hartford JT; Endicott J; Kornstein SG; Allgulander C; Wohlreich MM; Russell JM; Perahia DG; Erickson JS
    Prim Care Companion J Clin Psychiatry; 2008; 10(3):197-204. PubMed ID: 18615176
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The prognostic significance of brain-derived neurotrophic factor (BDNF) for phobic anxiety disorders, vegetative and cognitive impairments during conservative treatment including adaptol of some functional and organic diseases of nervous system].
    Zhivolupov SA; Samartsev IN; Marchenko AA; Puliatkina OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(4):37-41. PubMed ID: 22810739
    [TBL] [Abstract][Full Text] [Related]  

  • 74. BDNF and Artemin are increased in drug-naïve non-depressed GAD patients: preliminary data.
    Pallanti S; Tofani T; Zanardelli M; Di Cesare Mannelli L; Ghelardini C
    Int J Psychiatry Clin Pract; 2014 Oct; 18(4):255-60. PubMed ID: 24994477
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression.
    Mikoteit T; Beck J; Eckert A; Hemmeter U; Brand S; Bischof R; Holsboer-Trachsler E; Delini-Stula A
    Psychopharmacology (Berl); 2014 Aug; 231(15):2955-65. PubMed ID: 24562062
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
    Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
    J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies.
    Endicott J; Russell JM; Raskin J; Detke MJ; Erickson J; Ball SG; Marciniak M; Swindle RW
    J Clin Psychiatry; 2007 Apr; 68(4):518-24. PubMed ID: 17474806
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
    Ghosh R; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    Asian J Psychiatr; 2015 Dec; 18():37-41. PubMed ID: 26514447
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BDNF Val66Met polymorphism and plasma levels in Chinese Han population with obsessive-compulsive disorder and generalized anxiety disorder.
    Wang Y; Zhang H; Li Y; Wang Z; Fan Q; Yu S; Lin Z; Xiao Z
    J Affect Disord; 2015 Nov; 186():7-12. PubMed ID: 26209750
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
    Dunayevich E; Erickson J; Levine L; Landbloom R; Schoepp DD; Tollefson GD
    Neuropsychopharmacology; 2008 Jun; 33(7):1603-10. PubMed ID: 17712352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.